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SEK1/MKK4 Is Required for Maintenance
of a Normal Peripheral Lymphoid Compartment
but Not for Lymphocyte Development
humans, such signals are regulated in all cells by the Ras
superfamily of small GTPases and involve sequential
phosphorylation of distinct cascades of mitogen- and
stress-activated protein kinases (MAPKs and SAPKs,
respectively) (Davis, 1993; Marshall, 1995; Kyriakis and
Wojciech Swat,1,2 Keiko Fujikawa,2 Soula Ganiatsas,1
Di Yang,6 Ramnik J. Xavier,4 Nancy L. Harris,5
Laurie Davidson,1 Roger Ferrini,1 Roger J. Davis,7
Mark A. Labow,8 Richard A. Flavell,6 Leonard I. Zon,1,3
and Frederick W. Alt1,2,9
Avruch, 1996; Su and Karin, 1996; Treisman, 1996). The1Howard Hughes Medical Institute
SAPK cascade has the same basic characteristics andThe Children's Hospital
structure as the MAPK cascade but is functionally inde-2The Center for Blood Research
pendent and parallel. Unlike the MAPK pathway, whichDepartment of Genetics
is activated by growth factors and phorbol esters, theHarvard Medical School
SAPK pathway is induced primarily by proinflammatory3Dana-Farber Cancer Institute
cytokines and various stress stimuli (Hibi et al., 1993;Massachusetts General Hospital
Derijard et al., 1994). The upstream events leading to4Departments of Gastroenterology and
SAPK activation are thought to be regulated by the RhoMolecular Biology
subfamily proteins, e.g., Rac1 and Cdc42 (Coso et al.,5Department of Pathology
1995); however, their immediate downstream targetsHarvard Medical School
have not been clearly defined. A growing number ofBoston, Massachusetts 02115
individual SAPKs have been identified in mammalian6Section of Immunobiology
cells (Goedert et al., 1997; reviewed by Kiefer et al.,Howard Hughes Medical Institute
1997). Regulation of these SAPKs is complex, since mul-Yale University School of Medicine
tiple SAPK kinases and SAPK kinase kinases existNew Haven, Connecticut 06520
(Fanger et al., 1997).7Program in Molecular Medicine
The first kinase to be identified in the SAPK cascadeDepartment of Biochemistry and Molecular Biology
in mammalian cells was SEK1 (also termed MKK4 orUniversity of Massachusetts Medical School
JNKK). SEK1, which is a homolog of an essential Dro-Worcester, Massachusetts 01605
sophila melanogaster gene hemipterous (hep), was shown8Hoffmann-LaRoche
to specifically and directly phosphorylate SAPK (JNK1)Nutley, New Jersey 07110
(Sanchez et al., 1994). An additional activator of SAPK,
termed MKK7, was recently identified in mammalian
cells (Holland et al., 1997; Tournier et al., 1997; Wu et
Summary
al., 1997) and also shown to rescue hep mutant flies
(Holland et al., 1997). The latter result suggested the
SAPK is a member of the group of evolutionary con-
possibility that MKK7 may be, at least in part, redundant
served stress-activated kinases that mediate control in function to SEK1. However, SEK1-deficient embryonic
of cellular death and proliferation. In lymphocytes, the stem (ES) cellsand embryonic fibroblasts were defective
SAPK pathway has been implicated in signaling from in activation of SAPK and in transcriptional induction of
antigen, costimulatory, and death receptors; SEK1, the AP-1 complex (Yang et al., 1997; Ganiatsas et al.,
which directly activates SAPK, is required for early 1998). Moreover, inactivation of SEK1 in mice led to
embryonic development and has also been reported embryonic lethality (Yang et al., 1997; Ganiatsas et al.,
to be essential for normal lymphocyte development. 1998). Thus, SEK1 is encoded by an essential gene, the
In contrast to the latter findings, we have used RAG- function of which, at least in some cell types, is not
2±deficient blastocyst complementation to show that redundant to that of another expressed gene. Despite
SEK1-deficient embryonic stem cells support unim- these advances, the precise function of the SAPK path-
paired T and B lymphocyte development. Moreover, way in different cell types remains unclear. Thus, al-
mature SEK1-deficient lymphocytes are capable of though the SAPK pathway has been implicated in induc-
SAPK activation. Surprisingly, however, aging SEK1- tion of apoptosis in certain cell types (Xia et al., 1995;
deficient chimeric mice frequently develop lymphade- Cuvillier et al., 1996; Graves et al., 1996; Latinis and
nopathy and polyclonal B and T cell expansions. Thus, Koretzky, 1996; Verheij et al., 1996; Zanke et al., 1996;
SEK1 is not required for lymphocyte development, but Chauhan et al., 1997; Goillot et al., 1997; Kawakami et
is required for maintaining peripheral lymphoid ho- al., 1997; Yang et al., 1997), other studies have sug-
meostasis. gested that this pathway is not involved (Liu et al., 1996;
Lenczowski et al., 1997).
Introduction The function of the SAPK signalingpathways has been
studied extensively in lymphoid cells. Recent studies
A series of evolutionarily conserved signal transduc- have concluded that SEK1 plays an important role in
tion pathways links events on the cell surface with acti- preventing apoptosis in CD41CD81 immature thymo-
vation or suppression of transcription. From yeasts to cytes and B2201IgM2 bone marrow cells by mediat-
ing survival signals that protect such cells from pro-
grammed or CD95/Fas-induced apoptosis (Nishina et9 To whom correspondence should be addressed (e-mail: alt@rascal.
med.harvard.edu). al., 1997a, 1997b). Moreover, it has been concluded that
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SEK1 deficiency severely impairs T and B cell develop-
ment (Nishina et al., 1997a, 1997b). In mature T cells, the
SAPK pathway has been implicated in signal integration
following stimulation via antigen and costimulatory re-
ceptors that leads to activation of AP-1±directed tran-
scription (Rincon and Flavell, 1994; Su et al., 1994). In
this context, SEK1-deficient T cells were reported to
display defective responses to CD28 stimulation in vitro,
but not in vivo (Nishina et al., 1997b), although it is
unclear whether SAPK activation was affected in such
cells. It has also been demonstrated that stimulation of
B cells through the CD40 receptor, a member of the
tumor necrosis factor receptor family, preferentially in-
duces SAPK pathway (Berberich et al., 1996), although,
again, the exact role for SAPK in signaling by CD40 is
not known.
We used a gene-inactivation approach to study the
potential roles of the SAPK pathway in lymphocytes.
Because homozygous inactivation of the SEK1 gene in
mice leads to embryonic lethality (Yang et al., 1997;
Ganiatsas et al., 1998), we used the RAG-2±deficient
blastocyst complementation approach to assay ES cell
lines homozygous for two different SEK1 inactivating
mutations for the ability to generate functional B and T
lymphocytes in mice (Chen et al., 1993).
Results
SEK1 Is Not Required for Primary B or T
Lymphocyte Development
SEK1 has been reported to be required for primary de-
velopment of T and B lymphocytes based on studies that
used SEK12/2 ES cells for RAG-2±deficient blastocyst
complementation (Nishinaet al., 1997a, 1997b). To study
the development of lymphoid cells in the absence of
SEK1, we also tested SEK1-deficient ES cells by the
RAG-2±deficient blastocyst complementation method
(Chen et al., 1993). Because our initial studies on one
clone of SEK12/2 ES cells gave results different from
those of the reported studies, we went on to use an
additional, independently targeted, SEK1-deficient ES Figure 1. Reconstruction of the Lymphoid System in SEK12/2/RAG-
cell clone (Yang et al., 1997; Ganiatsas et al., 1998). In 22/2 Chimeric mice: SEK1 Is Not Required for Normal Primary Devel-
our analyses, these two SEK1-deficient ES cell clones opment of B and T Lymphocytes
gave essentially identical results, which differ funda- Single-cell suspensions of bone marrow (A), thymus (B), spleen (C),
or lymph nodes (D) from wild-type mice (left, 1/1) or SEK12/2/mentally from the conclusion of Nishina et al. (1997a).
RAG-22/2 chimeric mice (right, 2/2) were stained with fluorescentSEK12/2/RAG-22/2 chimeric mice with high ES cell
antibody conjugates and analyzed by flow cytometry. Data are dis-contribution (see Experimental Procedures) developed
played as dot plots with logarithmic scale. Numbers indicate per-
populations of B2201CD432 and B2201IgM1 mature B centages of lymphocyte populations. The results shown are repre-
cells in bone marrow that were indistinguishable from sentative of six wild-type (129 strain) and six SEK12/2/RAG-22/2
those of normal mice, indicating that differentiation of chimeric mice with strong ES cell contributions (n 5 4, clone GC7
and n 5 2, clone 59) analyzed at the age of 4±6 weeks. Not all miceB cells proceeded unperturbed in the absence of SEK1
were analyzed by all protocols.(Figure 1A). Furthermore, spleens and lymph nodes of
young (,6 weeks old) chimeric mice contained essen-
tially normal populations of mature B2201IgM1IgD1 B terms of total cell numbers (total numbers of SEK12/2
and wild-type thymocytes were 81.2 6 28.0, n 5 6,cells that, like those of wild-type mice, were surface-
positive for CD23, I-Ab, CD44, CD62L, and CD25 (Figure and 90.8 6 20.5, n 5 6, respectively). Moreover, SEK1-
deficient thymocytes exhibited a normal distribution of1C and data not shown). In addition, CD5 expression
on B1-B cells in the peritoneal cavity was normal (data CD3 and the expected frequencies of cells positive for
TCRVb8 and Vb6 (data not shown). Finally, young (,6not shown). Similarly, SEK12/2/RAG-22/2 chimeras with
high ES cell contribution also developed normal num- weeks old) SEK12/2/RAG-22/2 chimeric mice contained
lymph node and splenic T cell populations phenotypi-bers of CD41CD81, CD41CD82, and CD42CD81 thymo-
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Figure 2. Activation of SAPK Can Occur in
SEK1-Deficient B and T Cells Stimulated via
Antigen- or Costimulatory Receptors
(Top) Western blot analysis of wild-type (129
strain) (1/1) and SEK12/2 chimeric (2/2)
spleen cell suspensions either untreated or
activated with antibodies to CD40 (2 or 10
min) or IgM (2 or 10 min). Western blots were
probed with specific antisera to phosphory-
lated SAPK and phosphorylated p38. Control
Western blots for total p38 are also shown.
(Bottom) Western blot analysis of wild-type
(129 strain)(1/1) and SEK1 chimeric (2/2)
lymph node cell suspensions either untreated
or activated with antibodies to CD3 alone (2
or 10 min) or CD3 in combination with CD28
(2 or 10 min). Western blots were probed with
specific antisera to phosphorylated SAPK.
The results are representative of three inde-
pendent experiments.
of CD4, CD8, CD3, HSA, TCRab, TCRVb8, TCRgd, with anti-CD3 antibodies also led to induction of SAPK,
Thy1.2, CD44, CD62L, and CD25 (Figure 1D and data which was augmented by costimulation with anti-CD28
not shown). antibodies (Figure 2, bottom). However, phosphorylated
Based on these findings, we conclude that the SEK1 p38 levels were below the detection limit of our assay
kinase is not required for the development of normal even in wild-type T cells (data not shown). These findings
numbers of B and T lymphocytes that phenotypically are suggest that SAPK and p38 can be activated in the
indistinguishable from those of wild-type mice. These absence of SEK1 in lymphocytes by phosphorylation via
results and conclusions contrast sharply with those of other kinases, such as MKK7 and MKK3/6, respectively.
other studies in which SEK1 deficiency was reported to
impair development of both the B and T lineages (Ni- Susceptibility of SEK1-Deficient Double-Positive
shina et al., 1997a, 1997b).
Thymocytes to Fas- or CD3-Induced
Killing Is NormalActivation of SAPK Can Occur in SEK1-Deficient B
A number of recent studies have implicated the SAPKand T Cells Stimulated via Antigen Receptors
pathway in a mechanism of induction of apoptosis inor Costimulatory Receptors
various cell types (reviewed by Cosulich and Clarke,In lymphocytes, SAPK and p38 activation can be trig-
1996). However, a recent study has concluded that SEK1gered by antigen receptors and costimulatory receptors,
mediates survival signals in double-positive (DP) thymo-including CD40 and CD28. To examine whether signal-
cytes by protecting such cells from CD95/Fas- or CD3-ing induced by these receptors in SEK1-deficient lym-
induced apoptosis (Nishina et al., 1997a). To explore thisphocytes leads to activation of SAPK and p38 kinase,
issue, we compared the susceptibility of SEK1-deficientwe purified B and T cells from SEK12/2/RAG-22/2 or
and normal DP cells to anti-Fas antibody±induced killingwild-type mice and stimulated them in vitro with various
in vitro (Figure 3). Surprisingly, we observed no signifi-antibodies. The activity of SAPK and p38 kinases was
cant differences in the efficiency of Fas-induced killinganalyzed by Western blotting with phospho-specific an-
of SEK1-deficient and wild-type thymocytes over atibodies. Both wild-type and SEK1-deficient B cells
broad range of antibody concentrations and at varioustreated with anti-IgM or anti-CD40 antibodies induced
times of the assay (Figure 3 and data not shown). Inphosphorylation of the SAPK and p38 kinases (Figure
2, top). Stimulation of SEK1-deficient or wild-type T cells accord with these findings, we detected no differences
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induce significant proliferation) supplemented with anti-
CD28 plus or minus exogenous IL-2, and observed no
significant differences between mutant and wild-type
cells (Figure 4B). We also tested for anti-CTLA4 inhibi-
tion of CD3- and CD28-induced proliferation and, again,
found no differences between SEK12/2 and wild-type T
cells (Figure 4B).
SEK1-deficient and normal B cells proliferated equally
well in response to various mitogens, such as anti-CD40
antibodies or lipopolysaccharide (LPS) (Figure 4C). How-
ever, when treated with anti-IgM antibodies, the prolifer-
ation of SEK12/2 B cells was reduced compared with
that of wild-type B cells (Figure 4D). Measurements of
cell survival of SEK1-deficient and wild-type B cells un-
der these culture conditions failed to reveal any evi-
dence of increased susceptibility to IgM-induced cell
Figure 3. Susceptibility of SEK1-Deficient CD41CD81 Thymocytes death (data not shown). Thus, the reduced proliferative
to CD95/Fas-Induced Killing responses of SEK1-deficient B cells most likely result
Thymocyte suspensions prepared from wild-type (diamonds, 1/1) from a diminished rate of entrance into or progression
or SEK12/2/RAG-22/2 (squares, 2/2) mice were cultured in vitro in
through the cell cycle.the presence of various concentrations of antibodies to CD95/Fas,
as indicated (micrograms per milliliter). Wild-type thymocytes cul-
tured in media alone (CTRL, filled circle) were used as a control.
Lymphadenopathy and PlasmacytosisCells were harvested at 24 hr and their viability analyzed by flow
cytometry. Percentages of viable CD41CD81 thymocytes at the end in SEK12/2/RAG-22/2 Chimeric Mice
of the assay are plotted versusconcentration of stimulatory antibody When examined at the age of 2±6 months, 38% (5 of
in semilogarithmic histograms. Standard deviations are indicated 13) of SEK1-deficient chimeric mice exhibited grossly
by vertical lines. The results are representative of four independent
visible lymphadenopathy, with 3- to 20-fold enlargementexperiments.
of lymph node mass and cell numbers compared to
wild type; lymphadenopathy was most prominent in the
cervical, axial, and brachial regions (Figures 5A and 5B).
in Fas expression levels between SEK1-deficient and In affected mice, both B and T lymphocyte numbers
normal DP cells (data not shown). We also used an were increased (Figures 5A and 7A); this did not appear
alternative protocol to induce the death of DP thymo- to result from tumor formation since Southern blot
cytes by stimulation with anti-CD3 antibodies, and we assays for JH or Jb rearrangements revealed noevidence
observed no differences between SEK1-deficient and of clonally rearranged populations (above a background
normal cells (data not shown). threshold of approximately 5%; data not shown). Lymph
We conclude that SEK1 is not required to protect DP nodes from 2- to6-month-old SEK12/2/RAG-22/2 chime-
thymocytes from cell death. Furthermore, SEK1 does ras contained reactive follicles with germinal centers
not appear to have an essential role in enhancing the and prominent numbers of plasma cells in the interfollic-
susceptibility of these cells to death induction. There- ular regions and medullary cords (Figures 6A±6F). In
fore, any potential role of SEK1 in these processes in accord with the latter findings, we observed a 5- to 20-
normal DP thymocytes must be redundant with that of fold increase in percentages and total numbers of lymph
another activity. In addition, we found that anti-CD40± node Syndecan-11B220lowCD23low ªlargeº cells, a stain-
activated SEK1-deficient B cells were susceptible to ing pattern characteristic of terminally differentiated
CD95/Fas-antibody mediated killing, similar to the wild- plasma cells (Figure 7B). SEK12/2 chimeric mice with
type cells (data not shown). lymphadenopathy also had a 2- to 5-fold increase in
percentages and total numbers of lymph node B and T
lymphocytes that lost expression of CD62L (MEL14), aActivation and Proliferation of
SEK1-Deficient Lymphocytes phenotype ordinarily associated with a transition from
ªnaiveº to ªactivatedº cells (Figure 7A). In accord withTo determine whether signaling by antigen and costimu-
latory receptors was impaired in SEK1-deficient T and this finding, loss of CD62L expression was paralleled
by increased light scatter (cell size) and expression ofB lymphocytes, we assayed for expression of various
activation markers. These studies showed that induced CD44 (data not shown).
We conclude that SEK12/2/RAG-22/2 chimeras showexpression of CD69, CD23, class II antigens (I-Ab), B7±1,
and CD95/Fas in SEK1-deficient T and B lymphocytes, a polyclonal expansion of both B and T lymphocytes
within peripheral lymphoid organs. Our findings furtherrespectively, was indistinguishable from that of normal
cells (data not shown). Furthermore, SEK1-deficient T indicate that these expansions may be accompanied by
activation of both T and B cells and the accumulationcells proliferated in response to treatment with anti-CD3
in a manner indistinguishable from normal, both in the of terminally differentiated B cellsÐa process that can
be an outcome of their activation (Shultz and Green,presence or absence of exogenously added interleukin-2
(IL-2) (Figure 4A). To test whether CD28 function re- 1976; Shultz et al., 1984; Bories et al., 1995; Hibbs et
al., 1995; Nishizumi et al., 1995; Chan et al., 1997). Inmained intact, we stimulated SEK12/2 T cells with sub-
optimal concentrations of anti-CD3 (which alone did not this context, we also observed a modest increase in the
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Figure 4. Proliferative Responses of SEK1-
Deficient Lymphocytes to Stimulation via An-
tigen- or Costimulatory Receptors
Purified lymph node T cells (A and B) or
spleen B cells (C and D) from wild-type (open
bars) or SEK12/2/RAG-22/2 chimeric mice
(filled bars) were cultured in media alone or
in the presence of various concentrations of
stimulatory antibodies (indicated in micro-
grams per milliliter) to CD3e alone (A) or CD3e
(0.1 mg/ml) in combination with CD28 (2 mg/
ml) or CTLA4 (2 mg/ml) (B), CD40 or LPS (C),
or IgM (D). Proliferation was determined at
48 hr by incorporation of [3H]thymidine and
scintillation counting. The data are displayed
as raw counts-per-minute values (indicated
in thousands). The results are representative
of five independent experiments. Standard
deviations are shown as vertical lines. All
assays were conducted in triplicate.
number of CD62L-negative lymph node cells, compared likely that the previously analyzed ES cells may have had
some other alteration, separate from complete SEK1to that of wild-type lymph nodes, in several SEK12/2/
RAG-22/2 chimeras with no gross evidence of lymph- inactivation, that adversely affected their ability to com-
pletely reconstitute B and T lineage cell populations inadenopathy, suggesting that lymphocyte activation
may precede abnormal enlargement of lymph nodes the context of RAG-2±deficient blastocyst complemen-
tation. Such adverse effects may be generated as a(Figure 7A).
result of negative effects of inserted marker genes on
adjacent loci (Koyasu et al., 1994; Ohno et al., 1994) orDiscussion
the general loss of the ability of ES cells to contribute
to chimeras secondary to culturing (Chen and Alt, 1994).SEK1 Is Not Required for Normal Lymphocyte
Development or Induction of Cell Death
Our studies demonstrate that SEK1 is not required for SEK1 in Lymphocyte Activation
Several recent studies have shown that SEK1 deficiencythe development of normal numbers of primary lympho-
cytes. Likewise, we demonstrate that SEK1 also is not results in abrogation of AP-1±controlled transcription in
both ES cells and embryonic fibroblasts and is lethal torequired for protection of DP thymocytes or peripheral
T lymphocytes from cell death. Both of these findings the murine embryo (Yang et al., 1997; Ganiatsas et al.,
1998). Therefore, it is clear that the activity of SEK1, atwere surprising, since they contradicted the conclusions
of other recent studies that employed RAG-2±blastocyst least in certain cells, is essential and is not provided by
other expressed kinases, including the newly discov-complementation with a different line of SEK1-targeted
ES cells (Nishina et al., 1997a, 1997b). Therefore, we ered MKK7 kinase (Holland et al., 1997; Tournier et al.,
1997; Wu et al., 1997). Since SEK1 has been consideredconfirmed these results by assaying lymphocytes de-
rived from two independently targeted SEK12/2 ES cell to be the major activator of SAPK in all cells, our finding
that SAPK and p38 kinase induction was not obviouslyclones that were generated by replacement of two dis-
tinct, nonoverlapping regions of the SEK1 gene encod- altered in SEK12/2 versus wild-type B or T cells stimu-
lated by antigen and costimulatory receptors was signifi-ing amino acids 211±268 (including the dual phosphory-
lation sites) or 655±705 (encompassing the catalytic cant. Thus, this result shows that the molecular targets
of SAPK can be controlled by surface receptors in thedomain) (Yang et al., 1997; Ganiatsas et al., 1998). Fur-
thermore, our results agree with recent data showing absence of SEK1 in lymphocytes, indicating that other
activities have a redundant role with respect to SEK1 inthat introduction of a dominant-negative SEK1 kinase
in DP thymocytes does not influence susceptibility to inducing SAPK in these cell types. In accord with this
notion, several early and late activation events, includingFas killing (Alberola-Ila et al., submitted).
At present, we do not know the reasons for the differ- proliferation, that are triggered by antigen and costimu-
latory receptors, proceeded unperturbed in SEK1-defi-ences between our findings and those of earlier studies
(Nishina et al., 1997a, 1997b). However, it seems most cient lymphocytes. Altogether, our findings suggest that
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understand the cause of this expansion phenomenon,
although the absence of monoclonality tends to rule out
explanations associated with neoplastic or preneoplas-
tic states. Inactivation or inappropriate expression of a
variety of other genes in mice can result in lymphade-
nopathies that have some overlapping features with the
lymphadenopathy we observed in association with SEK1
deficiency. Such genes include those involved in pro-
cesses such as cell survival or death (McDonnell et al.,
1989, 1990; Cohen and Eisenberg, 1991; Strasser et al.,
1990, 1991; Nagata, 1994), regulation or transduction of
lymphocyte receptor or coreceptor signaling (Shultz and
Green, 1976; Shultz et al., 1984; Bories et al., 1995; Hibbs
et al., 1995; Muthusamy et al., 1995; Nishizumi et al.,
1995; Tivol et al., 1995; Waterhouse et al., 1995; Cham-
bers et al., 1997; Chan et al., 1997; Wang et al., 1997),
and interleukin/interleukin receptor signaling (Yoshizaki
et al., 1989; Brandt et al., 1990; Tepper et al., 1990;
Fisher et al., 1993; Rich et al., 1993; Cacalano et al.,
1994; Sadlack et al., 1994, 1995; Screpanti et al., 1995;
Willerford et al., 1995). Of these, there are phenotypic
differences substantial enough to argue against com-
plete overlap with the SEK1-deficient phenotype. Addi-
tional studies will be required to determine whether
some of the phenotypic similarities might stem from the
involvement of SEK1 in generating signals related to any
of these other molecules.
Experimental Procedures
Chimeric Mice and Blastocyst Complementation
Mice were housed in a specific pathogen±free, viral antibody±free
barrier-type facility at the Children's Hospital (Boston, MA). Experi-
mental and sentinel mice were tested by the Charles River Labora-
tory (Boston, MA). To generate chimeric mice, SEK12/2 ES cells
(clones GC7 and 59, respectively) (Yang et al., 1997; Ganiatsas et
al., 1998) were injected into RAG-2±deficient blastocysts, and the
resulting mice were tested at the age of 2±3 weeks by Southern
Figure 5. Enlargement of Lymph Node Tissue in Older SEK12/2/ blotting of DNA from tail biopsy samples and by flow cytometry of
RAG-22/2 Chimeric Mice and Expansion of B and T Cells peripheral blood lymphocytes. Sixteen of 38 pups (14 of clone 7
and 2 of clone 59) developed populations of peripheral blood B and(A) Atotal of 10 wild-type (129strain) (diamonds) or 13SEK12/2/RAG-
T cells, as assessed by staining with anti-Thy1.2 and anti-B22022/2 chimeric mice with (squares) or without (triangles) evidence
antibodies. Pups that had neither mature lymphocyte nor ES cellof enlarged lymph node tissue on macroscopic evaluation were
contribution to the DNA biopsy samples were excluded from furtheranalyzed at the age of 2±6 months. Single-cell suspensions were
analyses, as we and others routinely observe a lack of chimerismprepared; viable cells were counted with trypan blue; and the num-
in approximately 50% of mice that are born following injection ofbers of lymph node B and T cells were calculated from the percent-
normal ES cells into blastocysts. The remaining mice were furtherages of B2201IgM1 or CD41CD82 and CD42CD81 cells, respec-
analyzed at ages between 4 weeks and 6 months. Since incompletetively, as analyzed by FACS (see Figure 1). Each point on the plot
reconstitution of central lymphoid organs is frequently observed inrepresents an individual mouse.
the RAG-2±deficient blastocyst complementation, chimeric mice in(B) Peripheral lymph nodes from a 6-month-old wild-type mouse
which fewer than 90% of total cells in thymus or bone marrow(129 strain) (left) next to those from a SEK12/2/RAG-22/2 mouse
stained with anti-Ly9.1 antibodies (distinguishing between ES cell±(right).
and RAG-2±deficient blastocyst±derived cells) were excluded from
these analyses. Such incompletely reconstituted mice often contain
SEK1-redundant activities are differentially present in fewer DP thymocytes and B cells (F. W. A. et al., unpublished data).
some cell types or signaling pathways, or both. In this
regard, we observed diminished proliferation of SEK1-
Flow Cytometry Analyses
deficient B cells to anti-IgM antibody, even though both Single-cell suspensions of lymphoid cells were prepared and viable
anti-CD40 antibodies or LPS were able to induce normal cells were counted under a microscope with trypan blue. Cell sus-
proliferation of these cells. Therefore, the signaling path- pensions were stained with antibodies according to standard proce-
dures. The following antibody conjugates were used (PharMingen):ways linked to surface immunoglobulin in B cells may
phycoerythrin (PE)±H129.19 (anti-CD4); fluorescein isothiocyanatehave a distinct requirement for SEK1 from the CD40 or
(FITC)±, PE-, cytochrome C (CyC)±, or biotin-53-6.7 (anti-CD8a);LPS pathways.
FITC- or biotin-30C7 (anti-Ly9.1); PE-3C7 or FITC-7D4 (anti-IL2Ra);
FITC-145±2C11 (anti-CD3e); FITC-F23.1 (anti-TCR-Vb8); biotin-RR4-6
A Role for SEK1 in the Regulation of the (anti-TCR-Vb6); PE-53-7.3 (anti-CD5); PE-, FITC-, or CyC-RA3-6B2
Peripheral Lymphocyte Pool (anti-B220); FITC-7G6 (anti-CD21/35); FITC-B3B4 (anti-CD23); PE-
We have observed significant lymphadenopathy in 37.51 (anti-CD28); FITC-S7 (anti-CD43); PE-IM7 (anti-CD44, Pgp-1);
FITC- or PE-MEL14 (anti-CD62L); PE- or biotin-H1.2F3 (anti-CD69);SEK12/2/RAG-22/2 chimeric mice. Currently, we do not
SEK1/MKK4 Function in Lymphocytes
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Figure 6. Lymphadenopathy, Follicular Hyperplasia, and Plasmacytosis in SEK12/2/RAG-22/2 Chimeric Mice
Histological features of lymph nodes from normal and SEK1-deficient mice. Cross sections of wild-type (A) and SEK12/2 (B) lymph nodes
stained with hematoxylin and eosin (original magnification, 103). SEK12/2 lymph nodes show multiple follicles with germinal centers (C, arrows)
(original magnification, 1003); sheets of mature plasma cells in interfollicular areas and medullary cords (D) (original magnification, 4003);
germinal centers with the usual mixture of centrocytes and centroblasts and numerous cells undergoing apoptosis (E, arrows) and numerous
mast cells present in medullary cords (F, arrows) (original magnification, 4003).
FITC-16-10A1 (anti-CD80/B7±1); PE- or FITC-53-2.1 (anti-CD90.2/ were fixed in acetone and stained with Hematoxylin-2 and Eosin-Y
(Richard-Allen Scientific) according to standard procedures.Thy1.2); PE-Jo2 (anti-CD95/Fas); biotin-AMS9.1 (anti-IgDa); FITC-
or biotin-II/41 (anti-IgM); andFITC-AF6-120.1 (anti-I-Ab). Biotinylated
antibodies were detected with streptavidin-PE, or streptavidin-CyC T and B Cell Stimulation and Proliferation Assays
T cells were purified from lymph node cell suspensions by magnetic(PharMingen). FACScalibur flow cytometer (Becton-Dickinson) was
used with CellQuest software. Data are displayed as histograms or sorting and removal of B cells with anti-immunoglobulin±coated
Dynabeads (Dynal) to avoid receptor cross-linking during the purifi-dot plots with logarithmic scales. Each plot represents analysis of
at least 2 3 104 events collected as listmode files. cation process, using standard procedures. The purity of the re-
sulting T cells exceeded 90%, as confirmed by fluorescence-acti-
vated cell sorter (FACS) analysis. B cells were purified from spleenWestern Blot Analysis
Following stimulation, cells were lysed in RIPA buffer containing cell suspensions by magnetic removal of cells stained with biotinyl-
ated antibodies anti-Thy1.2, CD4, CD8, CD3, Mac-1, and Gr-1 usingprotease and phosphatase inhibitors, and postnuclear lysates were
prepared and resolved by SDS±polyacrylamide gel electrophoresis. streptavidin-coated Dynabeads. Purity was confirmed in each prep-
aration by FACS analysis and exceeded 85%. Lymphocytes wereImmunoblot analysis was performed by probing with polyclonal anti-
bodies to SAPK, phosphorylated SAPK (Thr183/Thr185) (New En- cultured in RPMI 1640 medium supplemented with 10% fetal calf
serum, penicillin/streptomycin, L-glutamine, sodium pyruvate, non-gland Biolabs), p38, and phosphorylated p38 (New England Biolabs)
and SEK1 (Santa Cruz). Immune complexes were detected by en- essential amino acids, and 2-mercaptoethanol. To measure the in-
duction of kinase activity, T cells were stimulated at a concentrationhanced chemiluminescence (Amersham).
of 5 3 106 cells/ml with either soluble anti-CD3e (10 mg/ml) and/or
anti-CD28 (2 mg/ml) (PharMingen), as indicated, and B cells wereHistological Analysis
Specimens for light microscopy were harvested, frozen in liquid stimulated with soluble anti-IgM Fab2 fragments (10 mg/ml) (Rock-
land or Southern Biotechnology Associates), or anti-CD40 (1 mg/ml)nitrogen, and processed for cryosection. Cryostat sections (4 mm)
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